# Clene Inc.: filings

CLNN · Nasdaq · CIK 1822791 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/clnn.md) · [Financials](/companies/clnn/financials.md) · [Filings](/companies/clnn/filings.md) · [Insiders](/companies/clnn/insiders.md)

## Reports and events: 171 filings

Newest first, by EDGAR acceptance time (Eastern). Filter with ?form= one of: `periodic`, `8-K`, `10-K`, `10-Q`, `4`, `proxy`, `13dg`, `all`, or any form this company filed (4 318, 8-K 129, 424B3 21, 424B5 21, 3 18, 10-Q 17, CORRESP 16, UPLOAD 15, 3/A 12, SCHEDULE 13G/A 12, 4/A 11, EFFECT 10, SC 13G 10, 144 8, S-4/A 7, SC 13G/A 7, 10-K 6, DEF 14A 6, DEFA14A 6, S-3 6, S-8 5, SC 13D/A 5, ARS 4, PRE 14A 4, SD 4, SC 13D 3, 8-K/A 2, D 2, S-1 2, SEC STAFF LETTER 2, 25-NSE 1, 5 1, 8-A12B 1, 8-A12B/A 1, CERT 1, POS AM 1, PRER14A 1, S-1/A 1, S-3/A 1, S-3MEF 1, S-4 1, SCHEDULE 13G 1).

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-20 | 23:37 ET | [8-K](/filings/0001437749-26-032960.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001437749-26-032960 |
| 2026-10-19 | 12:05 ET | [8-K](/filings/0001437749-26-032882.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-032882 |
| 2026-09-16 | 21:13 ET | [8-K](/filings/0001437749-26-030581.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-030581 |
| 2026-08-14 | 12:35 ET | [8-K](/filings/0001437749-26-027837.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-26-027837 |
| 2026-08-14 | 12:01 ET | [10-Q](/filings/0001437749-26-027828.md) | Quarterly report, period 2026-06-30 | 0001437749-26-027828 |
| 2026-08-10 | 12:07 ET | [8-K](/filings/0001437749-26-026653.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-026653 |
| 2026-05-22 | 20:37 ET | [8-K](/filings/0001437749-26-018267.md) | 1.01 Entry into a material agreement; 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001437749-26-018267 |
| 2026-05-14 | 12:02 ET | [8-K](/filings/0001437749-26-016881.md) | 1.01 Entry into a material agreement; 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-26-016881 |
| 2026-05-14 | 11:54 ET | [10-Q](/filings/0001437749-26-016878.md) | Quarterly report, period 2026-03-31 | 0001437749-26-016878 |
| 2026-05-05 | 21:06 ET | [8-K](/filings/0001437749-26-014946.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-014946 |
| 2026-05-04 | 12:02 ET | [8-K](/filings/0001437749-26-014542.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-014542 |
| 2026-04-10 | 20:05 ET | [DEF 14A](/filings/0001437749-26-012018.md) | Proxy statement, period 2025-12-31 | 0001437749-26-012018 |
| 2026-03-17 | 11:00 ET | [10-K](/filings/0001437749-26-008502.md) | Annual report, period 2025-12-31 | 0001437749-26-008502 |
| 2026-03-17 | 22:15 ET | [8-K](/filings/0001437749-26-008482.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001437749-26-008482 |
| 2026-03-12 | 12:05 ET | [8-K](/filings/0001437749-26-007828.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-26-007828 |
| 2026-02-24 | 13:01 ET | [8-K](/filings/0001437749-26-005156.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-005156 |
| 2026-01-13 | 21:36 ET | [8-K](/filings/0001437749-26-001196.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-001196 |
| 2026-01-12 | 13:30 ET | [8-K](/filings/0001437749-26-001049.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-001049 |
| 2025-12-03 | 13:45 ET | [8-K](/filings/0001437749-25-036713.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001437749-25-036713 |
| 2025-12-03 | 13:01 ET | [8-K](/filings/0001437749-25-036712.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-25-036712 |
| 2025-11-13 | 13:03 ET | [8-K](/filings/0001437749-25-034621.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-25-034621 |
| 2025-11-13 | 12:51 ET | [10-Q](/filings/0001437749-25-034613.md) | Quarterly report, period 2025-09-30 | 0001437749-25-034613 |
| 2025-10-17 | 20:31 ET | [8-K](/filings/0001437749-25-031277.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-25-031277 |
| 2025-10-14 | 12:00 ET | [8-K](/filings/0001437749-25-030891.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001437749-25-030891 |
| 2025-09-25 | 12:01 ET | [8-K](/filings/0001437749-25-029846.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-25-029846 |
| 2025-09-05 | 20:21 ET | [8-K](/filings/0001437749-25-028485.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-25-028485 |
| 2025-08-14 | 12:41 ET | [8-K](/filings/0001437749-25-026690.md) | 1.01 Entry into a material agreement; 2.02 Results of operations; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001437749-25-026690 |
| 2025-08-14 | 12:02 ET | [10-Q](/filings/0001437749-25-026679.md) | Quarterly report, period 2025-06-30 | 0001437749-25-026679 |
| 2025-07-03 | 20:36 ET | [8-K](/filings/0001437749-25-022150.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-25-022150 |
| 2025-06-30 | 12:04 ET | [8-K](/filings/0001437749-25-021483.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-25-021483 |
| 2025-06-17 | 20:31 ET | [8-K](/filings/0001437749-25-020669.md) | 8.01 Other events | 0001437749-25-020669 |
| 2025-05-23 | 20:04 ET | [8-K](/filings/0001437749-25-018336.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001437749-25-018336 |
| 2025-05-07 | 12:03 ET | [10-Q](/filings/0001437749-25-014918.md) | Quarterly report, period 2025-03-31 | 0001437749-25-014918 |
| 2025-05-07 | 12:02 ET | [8-K](/filings/0001437749-25-014917.md) | 2.02 Results of operations; 3.01 Delisting notice; 9.01 Financial statements and exhibits | 0001437749-25-014917 |
| 2025-04-28 | 11:58 ET | [8-K](/filings/0001437749-25-013230.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001437749-25-013230 |
| 2025-04-08 | 20:08 ET | [DEF 14A](/filings/0001437749-25-011400.md) | Proxy statement, period 2024-12-31 | 0001437749-25-011400 |
| 2025-04-08 | 12:00 ET | [8-K](/filings/0001437749-25-011309.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-25-011309 |
| 2025-03-27 | 12:32 ET | [8-K](/filings/0001437749-25-009484.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-25-009484 |
| 2025-03-24 | 20:03 ET | [10-K](/filings/0001437749-25-008956.md) | Annual report, period 2024-12-31 | 0001437749-25-008956 |
| 2025-03-24 | 13:14 ET | [8-K](/filings/0001437749-25-008869.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-25-008869 |
| 2025-03-12 | 12:00 ET | [8-K](/filings/0001437749-25-007120.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-25-007120 |
| 2025-01-30 | 21:31 ET | [8-K](/filings/0001437749-25-002265.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001437749-25-002265 |
| 2024-12-20 | 22:12 ET | [8-K](/filings/0001437749-24-038152.md) | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 2.03 New direct financial obligation; 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-24-038152 |
| 2024-12-10 | 13:32 ET | [8-K](/filings/0001437749-24-037061.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-24-037061 |
| 2024-11-13 | 13:05 ET | [8-K](/filings/0001437749-24-034668.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001437749-24-034668 |
| 2024-11-13 | 12:30 ET | [10-Q](/filings/0001437749-24-034663.md) | Quarterly report, period 2024-09-30 | 0001437749-24-034663 |
| 2024-10-23 | 12:00 ET | [8-K](/filings/0001437749-24-031805.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001437749-24-031805 |
| 2024-10-02 | 20:38 ET | [SC 13D/A](/filings/0000897069-24-001916.md) | Ownership report, active investor, amended | 0000897069-24-001916 |
| 2024-09-30 | 21:11 ET | [8-K](/filings/0001437749-24-030269.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001437749-24-030269 |
| 2024-09-30 | 20:45 ET | [8-K](/filings/0001437749-24-030263.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-24-030263 |

Page 1 of 4. [Older](/companies/clnn/filings.md?page=2)
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:15 ET. No prices; not investment advice.